← Back to feed

Oxford Biodynamics

OBD · AIM · Health Care · mcap £16m today, £16m on 27 Aug

New CEO resets, then buys · Early 1/3

Pattern evidence · every line sourced

New CEO or CFO, 27 Aug: The appointment follows the Company's announcement of 30 June 2026 regarding Mr Compton's appointment as Chief Executive Officer and the completion of regulatory due diligence by the Company's Nomad. RNS
Watch: next signal would be “Guidance cut” – “below expectations” or a profit warning, within 180 days.

AI summary with checked claims arrives with the nightly run. These lines are the matched extracts.

All announcements

All RNS · 40 Key events · 18 Pattern signals · 1

01 Oct 26

Extension of Timetable in relation to Placing

Oxford BioDynamics Plc (AIM: OBD), the 3D Genomics Company, announced on 10 August 2026 that it had conditionally raised £9.15m through a placing of 9,150,000,000 new ordinary shares (the “Placing Shares”) at a price of £0.001 per Placing Share (the “Placing”).
RNS 9802755 ↗
03 Sep 26

Orion reveals link between five fatigue conditions

Study finds five major fatigue-related conditions converge on shared regulatory networks when analysed using Oxford BioDynamics' EpiSwitch® Orion platform
RNS 9754462 ↗
27 Aug 26

SIGNAL 1 New CEO or CFO

The appointment follows the Company's announcement of 30 June 2026 regarding Mr Compton's appointment as Chief Executive Officer and the completion of regulatory due diligence by the Company's Nomad.
Board Appointment · RNS 9742146 ↗
13 Aug 26

Partnership with Dubai London Clinics & Hospitals

Oxford BioDynamics partners with Dubai London Clinics & Hospitals to bring EpiSwitch® PSE to the UAE
RNS 9719108 ↗
10 Aug 26

Fundraising, Posting of Circular & Notice of GM

Oxford, UK - 10 August 2026 - Oxford Biodynamics Plc (AIM: OBD), the international biotechnology company advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch® Orion, its cloud-based 3D genomics platform for pharma and...
RNS 9713768 ↗
28 Jul 26

First commercial agreement for EpiSwitch® Orion

Oxford BioDynamics signs first commercial agreement for its EpiSwitch® Orion 3D genomics discovery platform
RNS 9689971 ↗
30 Jun 26

US contract sales partnership

("OBD" or the "Company" and, together with its subsidiaries, the "Group")
RNS 9643232 ↗
30 Jun 26

Half-year Results

("OBD" or the "Company" and, together with its subsidiaries, the "Group")
RNS 9643173 ↗
30 Jun 26

Appointment of Chief Executive Officer New CEO

("OBD" or the "Company" and, together with its subsidiaries, the "Group")
RNS 9643006 ↗
15 Apr 26

Board Appointment

("OBD" or the "Company" and, together with its subsidiaries, the "Group")
RNS 9520343 ↗
03 Mar 26

OBD to present at PMWC 2026

("OBD" or the "Company" and, together with its subsidiaries, the "Group")
RNS 9455772 ↗
17 Feb 26

Change of Nominated Adviser

("OBD" or the "Company" and, together with its subsidiaries, the "Group")
RNS 9433547 ↗
26 Jan 26

Directorate Change

("OBD" or the "Company" and, together with its subsidiaries, the "Group")
RNS 9385679 ↗
22 Dec 25

Publication of 2025 Annual Report

("OBD" or the "Company" and, together with its subsidiaries, the "Group")
RNS 9312848 ↗
16 Dec 25

Preliminary Results and Notice of AGM

("OBD" or the "Company" and, together with its subsidiaries, the "Group")
RNS 9298665 ↗
22 Oct 25

Fundraising, Posting of Circular & Notice of GM

The Placing and the Subscriptions (together the "Fundraising") are being carried out at an issue price of £0.003 per Ordinary Share of £0.001 each (the "Issue Price").
RNS 9185852 ↗
14 Oct 25

OBD in New Report on NHS Prostate Cancer Screening

Prostate Cancer Research NHS screening report highlights OBD's EpiSwitch PSE
RNS 9168773 ↗
08 Oct 25

OBD and UEA develop test for Chronic Fatigue

OBD and UEA develop breakthrough diagnostic test for Chronic Fatigue Syndrome
RNS 9156866 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.